Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Clinical Study of Personalized Tumor Neoantigen-based Peptide Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

NCT06752044 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Nanchang University as lead sponsor.

NCT NCT06752044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06752044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Clinical Study of Personalized Tumor Neoantigen-based Peptide Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
Lead sponsor
The First Affiliated Hospital of Nanchang University
Phase
Not applicable
Overall status
Recruiting
Start date
September 1, 2024
Completion date
February 28, 2027
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nsclc